Calico Life Sciences, a biotech founded by Alphabet and Arthur Levinson focused on the biology of aging and age-related diseases, has announced a setback.
The Californian firm has revealed disappointing initial top-line results from Regimen F of the HEALEY ALS Platform Trial evaluating fosigotifator (ABBV-CLS-7262) in adults with amyotrophic lateral sclerosis (ALS).
Fosigotifator is a eukaryotic initiation factor 2B (eIF2B) activator in development by Calico in collaboration with US drug major AbbVie (NYSE: ABBV) for the treatment of ALS and other disorders of the central nervous system.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze